2CJP
2CJP, also known as 4--2,3,4,5-tetrahydro-1H-2-benzazepine, is a serotonin receptor modulator of the phenethylamine, 2C, and N-benzylphenethylamine families. It is a cyclized phenethylamine analogue of 25B-NBOMe in which the N-benzylethylamine side chain has been cyclized to form a tetrahydrobenzazepine ring. The drug shows affinity for the serotonin 5-HT2A and 5-HT2C receptors. 2CJP was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.